Table II.
MMP2 expression, no. | |||
---|---|---|---|
Characteristics | Positive | Negative | P-value |
Age (years) | 0.95 | ||
≤50 | 7 | 39 | |
>50 | 17 | 92 | |
Tumor size (mm) | 0.02 | ||
≤20 | 19 | 71 | |
>20 | 5 | 60 | |
Lymph node status | 0.11 | ||
Negative | 17 | 70 | |
Positive | 7 | 61 | |
Histological grade | 0.17 | ||
1 | 2 | 25 | |
2 | 8 | 55 | |
3 | 14 | 51 | |
ER status | 0.075 | ||
Negative | 6 | 15 | |
Positive | 18 | 116 | |
PR status | 0.09 | ||
Negative | 9 | 28 | |
Positive | 15 | 103 | |
HER2 status | 0.002 | ||
Negative | 14 | 112 | |
Positive | 10 | 19 | |
Ki-67 | 0.45 | ||
<15% | 4 | 31 | |
≥15% | 20 | 100 | |
Molecular subtypes | 0.025 | ||
Luminal A | 2 | 32 | |
Luminal B | 11 | 75 | |
Luminal-HER2 | 7 | 12 | |
HER2-enriched | 3 | 7 | |
Triple-negative | 1 | 5 |
MMP2, matrix metalloproteinase 2; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor.